NCT04540796 : A Phase 1, First-in-Human, Dose Escalation Study of the JNJ-75348780 Bispecific Antibody Targeting CD3 and CD22 in Participants With NHL and CLL

Male or<br/>FemaleGender Male or
Female

RecruitingStatus Recruiting

Systemic<br/>Therapy TrialTypeSystemic
Therapy Trial

OnePhase One

18+Age Over 18

Blood<br/>CancersCancer LocationBlood
Cancers

Systemic therapy,Treatment | Blood / Myeloma / LymphomaB-Cell Non Hodgkin Lymphoma,Chronic Lymphocytic Leukaemia,Follicular Lymphoma,Leukaemia,Lymphoma,Mantle Cell Lymphoma

Trial Overview Read MoreRead more

This phase I trial is trying to find a safe and effective dose of a new targeted cancer drug, to treat patients with B-cell Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukaemia who have got worse, not responded or are unable to receive other treatment.
 

This trial is treating patients with B-cell Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL).

This is a systemic therapy trial.

You may be able to join this trial if:

  • You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.

You may be excluded from this trial if:

  • You have a certain disease or psychological condition.
  • You have had certain treatments, surgical procedures or drugs.

Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.

Clinical Summary Read MoreRead more

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Scientific Title

A Phase 1, First-in-Human, Dose Escalation Study of the JNJ-75348780 Bispecific Antibody Targeting CD3 and CD22 in Participants With NHL and CLL

Commercial Sponsor

Janssen-Cilag Pty Ltd

Summary

This trial consists of a screening phase, treatment phase and post-treatment phase. The total duration of the trial will be up to 2.7 years. Efficacy assessments will include radiographic image assessments, positron emission tomography scan, bone marrow assessment, endoscopy or colonoscopy, physical examinations. Safety will be monitored throughout the trial. The treatment phase will be split into two parts. Part A: Dose Escalation and Part B: Dose Expansion. In Part A, eligible patients will receive intravenous or subcutaneous JNJ-75348780 weekly, with doses escalated sequentially until a recommended dose is identified. Patients enrolled in Part B will receive JNJ-75348780 at the recommended dose.

Recruiting Hospitals Read MoreRead more

Olivia Newton-John Cancer Wellness & Research Centre
Heidelberg
Ms Samantha Chakar
samantha.chakar@austin.org.au
03 9496 3088

Trial Overview: General information about a clinical trial. This section provides an overview of who might be able to join this trial and what type of treatment is involved.

Next